Pharmaceutical News and Articles

TCBP Announces First Patient Completed the Full Dose Regimen in ACHIEVE Clinical Trial

EDINBURGH, Scotland, Sept. 22, 2024. TC BioPharm (Holdings) PLC ( TC BioPharm or the Company ), a clinical stage biotechnology company developing platform allog

FDA Approves Miplyffa (arimoclomol) for the Treatment of Niemann-Pick Disease Type C

Is It a Cold, Flu or COVID? An Expert Helps You Sort It Out

and can progress to more severe symptoms in some people. Are some people more at risk of developing colds, flu and COVID-19 than others The elderly, as well as

Workplace Stress Triggers: How to Spot Them, How to Cope

Workplace anxiety. Who hasn t experienced it However, if that anxiety is so strong that it hurts your performance or lingers for months, you might have a proble

FDA Approves First Flu Vaccine You Give Yourself at Home, FluMist

The days of waiting for a flu shot at your doctor s office or local pharmacy may be over The U.S. Food and Drug Administration on Friday approved FluMist nasal

Fussy Eater? It Might Be in Your Kid's Genes

Pulling your hair out in frustration with your finicky youngster genetics likely played a huge role in their eating habits, a new twins study FINDs. Fussy eatin

U.S. Whooping Cough Cases Rising, Especially in Teens, CDC Says

Whooping cough cases are climbing at the fastest pace in years as students across America return to school, U.S. health officials reported Thursday. In figures

FDA Says Drug Makers Will Stop Producing Fentanyl 'Lollipops'

Controversial fentanyl lollipops and similar products will no longer be made by drug makers, the U.S. Food and Drug Administration has announced. Known as TIRF

Stroke Rates Rising in Adults and Kids With Sickle Cell Disease

Stroke rates continue to rise among adults and children living with sickle cell disease, despite new standards of care meant to lower their risk, a new study fi

Adjuvant Pembrolizumab Improves Survival in Muscle-Invasive Urothelial Cancer

Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk muscle-invasive urothelial carcinoma af